Race and prostate cancer: genomic landscape

Nat Rev Urol. 2022 Sep;19(9):547-561. doi: 10.1038/s41585-022-00622-0. Epub 2022 Aug 9.


In the past 20 years, new insights into the genomic pathogenesis of prostate cancer have been provided. Large-scale integrative genomics approaches enabled researchers to characterize the genetic and epigenetic landscape of prostate cancer and to define different molecular subclasses based on the combination of genetic alterations, gene expression patterns and methylation profiles. Several molecular drivers of prostate cancer have been identified, some of which are different in men of different races. However, the extent to which genomics can explain racial disparities in prostate cancer outcomes is unclear. Future collaborative genomic studies overcoming the underrepresentation of non-white patients and other minority populations are essential.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Epigenomics
  • Genomics
  • Humans
  • Male
  • Mutation
  • Prostatic Neoplasms* / genetics
  • Prostatic Neoplasms* / pathology